- Previous Close
2.5700 - Open
2.5600 - Bid 2.3420 x --
- Ask 2.3740 x --
- Day's Range
2.3380 - 2.5940 - 52 Week Range
2.0560 - 4.9480 - Volume
27,439 - Avg. Volume
24,957 - Market Cap (intraday)
526.297M - Beta (5Y Monthly) 2.48
- PE Ratio (TTM)
4.99 - EPS (TTM)
0.4700 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: 5CV.F
View MorePerformance Overview: 5CV.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 5CV.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 5CV.F
View MoreValuation Measures
Market Cap
526.16M
Enterprise Value
11.37M
Trailing P/E
4.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.97
Price/Book (mrq)
0.73
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.52%
Return on Equity (ttm)
-54.30%
Revenue (ttm)
65.86M
Net Income Avi to Common (ttm)
-278.43M
Diluted EPS (ttm)
0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
202.52M
Total Debt/Equity (mrq)
10.37%
Levered Free Cash Flow (ttm)
-222.1M